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Abstract
Background: In rural south Asia, hypertension remains a significant public health issue with sub-optimal blood
pressure (BP) control rates. The goal of the trial is to evaluate the effectiveness and cost-effectiveness of a
multicomponent intervention (MCI) compared to usual care on lowering BP among adults with hypertension in
rural south-Asian communities. This article describes the statistical analysis plan for the primary and secondary
objectives related to intervention effectiveness based on clinical and patient-reported endpoints.
Methods/Design: The study is a cluster randomized trial which will enroll 2550 participants aged ≥ 40 years with
hypertension from rural communities in Bangladesh, Pakistan, and Sri Lanka. The unit of randomization is a cluster
defined by 250–300 households. Thirty clusters, 10 from each country, are randomized in a 1:1 ratio to either MCI or
usual care, stratified by country and their distance from the clinic. All participants will be assessed every six months
over a two-year period after baseline with measurements of systolic and diastolic BP, antihypertensive and statin
medication use, medication adherence, physical activity level, anthropometric parameters, smoking status, and
dietary habits. The primary objective is to assess the effectiveness of MCI as compared with usual care in terms of
mean change in systolic BP from baseline to final follow-up at two years. The primary outcome will be modelled
using a generalized linear mixed-model for repeated measures based on a participant-level analysis. The model will
include cluster random-effects and will use a non-independence residual correlation matrix to account for repeated
measures on the same participant. Sensitivity analyses for the primary endpoint will be based on multiple imputation
as well as pattern mixture model tipping point analyses. Secondary outcomes will be analyzed using the same
modeling approach as for the primary outcome, with appropriate distributions within the exponential family and
corresponding link functions.
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Discussion: The a priori statistical analysis plan will avoid reporting bias and data-driven analysis for the primary and
key secondary outcomes. The results of the study will provide evidence of the benefits and risks of the MCI for BP
control in rural communities in south Asian countries with low-resourced public health infrastructure.
Trial registration: Clinicaltrials.gov, NCT02657746. Registered on 14 January 2016.
Keywords: Cluster randomized trial, Hypertension, Statistical analysis plan, Blood pressure
Introduction
The control of blood pressure and risk attenuation-rural
Bangladesh, Pakistan, Sri Lanka (COBRA-BPS) trial is a
cluster randomized clinical trial to compare a multicom-
ponent intervention (MCI) to usual care. The overall goal
is to evaluate the effectiveness and cost-effectiveness of
MCI in adults aged ≥ 40 years with hypertension who
reside in rural communities of Bangladesh, Pakistan,
and Sri Lanka. MCI comprises the following five compo-
nents: (1) home health education (HHE) by government
community health workers (CHWs); (2) blood pressure
(BP) monitoring and stepped-up referral to a trained
general practitioner (GP) using a checklist; (3) trained
public and private providers in management of hyperten-
sion and using a checklist; (4) designated hypertension
triage counter and hypertension care coordinators in
government clinics; and (5) a financing model to compen-
sate for additional health services and provide subsides to
low-income individuals with poorly controlled hyperten-
sion. A detailed description of the COBRA-BPS trial
protocol has already been published [1]. It contained a
brief description of the primary effectiveness analysis. The
current article describes a more detailed statistical analysis
plan for the primary and secondary objectives for the
intervention effectiveness based on clinical and patient-re-
ported outcomes. At the time of writing, no post-baseline
outcomes for effectiveness has been analyzed in the trial.
The a priori statistical analysis plan will avoid reporting bias
and data-driven analysis. This article does not include an
analysis plan for other objectives such as evaluating cost-ef-
fectiveness of the intervention and patients’ experience dur-
ing the course of intervention through qualitative data.
These topics will be covered in separate papers.
Randomization
The trial is conducted in Bangladesh, Tangail District
(population 3.2 million), and Munshiganj District (popu-
lation 1.4 million); Pakistan, Thatta District (population
1.5 million); and Sri Lanka, Puttalam District (population
1.6 million). The unit of randomization was a cluster
defined by 250–300 households as defined by local admin-
istration according to CHW catchment area (each served
by 1–2 CHWs). These clusters were grouped in geograph-
ically contiguous administrative units (AUs) as defined by
the local governments (12 sub-districts in Tangail, six
subdistricts in Munshignaj, 30 union councils in Thatta,
12 medical officers of the health division in Puttalam
District) such that each unit is served by one government
clinic. First, in the selected district of each country, 10
administrative units were deliberately sampled, and the
respective government clinic was determined. Within each
AU in each country, eligible clusters were identified (one
cluster is defined as a village for Bangladesh, 2–5 neigh-
boring villages for Pakistan, and two Grama Niladhari
[GN] divisions for Sri Lanka). Each country measured the
distance of clusters from the respective government clinic
by a GPS device. In each AU, clusters were stratified into
two strata according to their distance to respective
government clinic: FAR and NEAR (a distance of ≤ 2 km
was defined as NEAR and > 2 km as FAR). In each arm
(usual care or MCI), three of the five AUs were randomly
sampled to be NEAR AUs so that the remaining two were
FAR. Then, one NEAR cluster from each NEAR AU and
one FAR cluster from each FAR AU were randomly
selected for participant recruitment. A minimum distance
of 10 km between randomized clusters were ensured.
Figure 1 shows a schematic diagram for cluster selection
criteria. In summary, randomization was stratified by
country as well as by the distance from the government
clinic, and AUs (equivalently, the sampled clusters)
were randomized in a 1:1 ratio to either MCI or usual
care within the six strata defined by the combination of
country and distance (NEAR versus FAR) using a com-
puter-generated randomization program at Singapore
Clinical Research Institute, Singapore.
Study assessments
Study assessments are summarized in Table 1. The majority
of the assessment will be performed at six-monthly home
visits up to two years from the baseline. The acceptable
tolerance in the six-monthly visits is ± 2 months. All
assessments will be performed by independent assessors
(masked to randomization status). More details of study
assessment forms, questionnaires, and checklists are avail-
able in the published protocol [1].
Sample size
The planned sample size is 2550 participants with hyper-
tension, corresponding to a target sample size of 85
hypertensive participants per cluster for each of the 10
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clusters per country in each of the three countries. Based
on findings from a previous feasibility study in rural
Bangladesh, Pakistan, and Sri Lanka [2], a conservative
intraclass correlation coefficient (ICC) of 0.02 was
considered. Assuming 80% participant retention rate
per cluster at two years after baseline (68 hypertensive
participants per cluster) and a two-sided type I error
rate of 5%, the trial will provide > 99% power for the
overall test to detect a difference between arms in SBP
reduction as small as 4 (SD 11) mm Hg [3–5]. The
study will use 5 mmHg as the clinically meaningful
difference between the two arms for reduction in SBP.
Pertaining to heterogeneity in the intervention effect
among the three countries, we assume that < 3 mmHg
difference in SBP is not clinically meaningful. Therefore,
the intervention effect will be considered heterogeneous
among countries if the difference in SBP reduction
between any two countries is ≥ 3 mmHg (SD 11) (for
example, a reduction in SBP of 3 mmHg in one country
and 9 mmHg in the other two countries; or reduction in
SBP is 3 mmHg in one country, 6 mmHg the in second,
and 9 mmHg in the third). The planned sample size pro-
vides > 80% power to detect heterogeneity (as defined
above) in intervention effects based on the following
assumptions: ICC of 0.02 and type I error rate of 0.16%
Fig. 1 Schematic diagram for cluster selection criteria in the
randomization Multicomponent intervention cluster; Usual care
cluster; Government clinic nearest to the randomized cluster;
Non-randomized cluster; Government clinic outside 10 km radius
of randomized cluster. Rectangles represent administrative units.
Dotted line surrounding a cluster represents a 10-km radius to the
cluster. Dotted line surrounding a government clinic represents a
2-km radium to the clinic. No usual care clusters are within a 10-km
radius of MCI clusters. Any usual care cluster should not be nearer to
a MCI government clinic than its own; similarly, any MCI cluster
should not be nearer to a usual care government clinic than its own
Table 1 Study assessments schedule
Assessments Study visits
Screening Baseline 6-monthly (until
2 years from baseline)
Informed consent ✓
Demographics
characteristics
✓
Systolic and diastolic blood
pressuresa
✓ ✓ ✓
Current blood pressure
medications
✓
Socioeconomic
characteristics
✓
Medical history ✓
Concomitant medications ✓ ✓
Family medical history ✓
Tobacco smoking status ✓ ✓
International physical
activity questionnaire
✓ ✓
Dietary questionnaire ✓ ✓
EQ-5D-5L questionnaire ✓ ✓b
MMAS-8 for
antihypertensive
medication adherence
✓ ✓
MMAS-8 for statins
adherence
✓
Adiposity measures (BMI,
waist circumference)
✓ ✓
Laboratory tests ✓ ✓b
Serum creatinine
Fasting blood glucose
Total cholesterol
High density lipoprotein
cholesterol
Low density lipoprotein
cholesterol
Triglycerides
Urine spot albumin
Urine spot sodium
Urine spot creatinine
Adverse/serious adverse
events
✓ ✓
Death ✓
aOnly measurements taken by independent assessors who will be masked to
randomization will be used for the analysis
bTo be assessed only at final follow-up visit
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(based on a Bonferroni adjustment for three pairwise
comparisons).
In addition to this, the trial has > 80% power to detect a
difference of 4 mmHg (SD 11) in SBP reduction between
the MCI and usual care arms for each country separately,
for an ICC of 0.02, a two-sided type I error rate of 5%, and
10 clusters of size 85 participants per country with 80%
participant retention rate per cluster at two years post
baseline (68 participants per cluster) (Fig. 2). Furthermore,
the high power also ensures that the main effect is
adequately powered even after adjusting for dropouts.
Therefore, the study is not over-powered for heterogeneity
or dropouts (missing data). Power and Sample Size (PASS)
version 14 software was used for the power calculations.
Based on our previous work in urban Pakistan, and
expecting a somewhat lower attrition rate in rural areas,
the attrition rate is likely to be < 15% at the end of
two years in the overall study; therefore, our assumptions
about follow-up rates are conservative [4].
Study objectives
Primary effectiveness objective
To assess the effectiveness of MCI compared to usual
care in terms of mean change in systolic blood pressure
(SBP) from baseline to final follow-up at two years post
baseline.
Secondary effectiveness objectives
To compare mean change from baseline, or proportion,
at the final follow-up at two years post baseline between
MCI and usual care arm for the following outcomes:
 BP controlled to target (SBP < 140 mmHg and
diastolic blood pressure [DBP] < 90 mmHg)
 Response (SBP < 140 mmHg and diastolic BP
< 90 mmHg, or ≥ 5 mmHg reduction in SBP at two
years from the baseline)
 Poorly controlled BP (SBP ≥ 160 mmHg or DBP
≥ 100 mmHg)
 DBP
 Anti-hypertension and statin medications use
 Anti-hypertensive medication and statins adherence
score assessed by the eight-item Morisky Medication
Adherence Scale (MMAS-8)
 Physical activity score assessed by International
Physical Activity Questionnaire (IPAQ)
 Cardiovascular events risk score assessed by
INTERHEART “Cholesterol” modifiable risk score
 Health-related quality of life assessed by 5-Level
EuroQol-5 Dimension (EQ-5D-5L) questionnaire
 Body mass index (BMI)
 Waist circumference
 Current smoking status
 Frequency of vegetables and fruits intake per week
Fig. 2 Statistical power for individual country and overall study at the planned sample size
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 Salt intake assessed by urine spot sodium-to-
creatinine ratio and 24-h urine sodium
 Incident diabetes
 Cholesterol level assessed by total cholesterol, high
density lipoprotein cholesterol, low density
lipoprotein cholesterol, and triglycerides
 Estimated glomerular filtration rate (eGFR)
 Urine albumin excretion
Table 2 lists definitions of the above outcomes at a
particular visit.
Exploratory effectiveness objectives
To compare mean change in SBP at the final follow-up
at two years post baseline between MCI and usual care
arms for the following sub-groups defined according to
baseline characteristics:
Table 2 Outcome definitions for effectiveness objectives
Outcome Measurement and definition
Systolic and diastolic blood pressure
(SBP/DBP)
Measured using a calibrated automated device (Omron HEM-7300 Blood Pressure Monitor) with the
individual in the sitting position. Three reading are taken at least 3 min apart. Mean of last two readings
will be used as the final measurement.
Blood pressure controlled to target SBP (mean of last 2 of 3 readings) is < 140 mmHg and DBP (mean of last 2 of 3 readings) is < 90 mmHg.
Response SBP (mean of last 2 of 3 readings) is < 140 mmHg and DBP (mean of last 2 of 3 readings) is < 90 mmHg, or
change in mean of last two readings from the mean of last two readings from the baseline is ≥ 5 mmHg.
Poorly controlled blood pressure SBP (mean of last 2 of 3 readings) is ≥ 160 mmHg or DBP (mean of last 2 of 3 readings) is ≥ 100 mmHg.
Anti-hypertensive and statin
medication usage
Information on any ongoing anti-hypertensive and statin medications will be classified into one of the
following medication classes: Angiotensin II Receptor Blocker or Angiotensin-Converting Enzyme Inhibitor,
Beta Blocker, Calcium Channel Blocker, diuretics, and statins.
Eight-item Morisky Medication
Adherence Scale (MMAS-8) scores
Self-reported medical adherence is measured by the MMAS-8, separately for anti-hypertensive medication
and statins [13–16]. MMAS-8 scores are calculated by summing all coded answers.
International Physical Activity
Questionnaire (IPAQ) scores
Total physical activity score (MET-min/week) and activity classification (Inactive, Minimally Active, and Highly
Active) are derived according to the IPAQ scoring guideline [17].
Cardiovascular events risk score The INTERHEART “Cholesterol” modifiable risk score provides a comprehensive numeric assessment of risk
factors for cardiovascular events [18]. The score is the sum of points for questions corresponding to
categories of these risk factors.
Five-level EuroQol-5 Dimension
(EQ-5D-5L) questionnaire index
The EQ-5D-5L is administered to assess a participant’s health status on the day of assessment. In addition, it
has a visual analogue scale (VAS) measuring health on a scale of 0 (The worst health you can imagine) to
100 (The best health you can imagine) [19].
The EQ-5D-5L index summarizing health status of the participants is calculated using the EQ-5D-5L value
set for England [20]. Currently, there is no value set available for Bangladesh, Pakistan, or Sri Lanka. However,
if any more suitable value set becomes available before the final data analysis, it will be used. The EQ-5D-5L
VAS is also considered as an additional health-related quality-of-life measure.
Body mass index Calculated as weight (kg) divided by height2 (m). Height is measured using standardized Portable
Stadiometer (Model SECA 213) in cm with graduation of 1 mm. Weight is measured using standardized
OMRON Digital Weight Scale (Model HN-286).
Waist circumference Measured as per the WHO STEPS protocol [21]. The measurement of waist circumference is made at the
approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest.
Current smoking status Individuals smoking tobacco on a daily basis, including cigarette, pipes, cigars, cheroots, cigarillos, and water
pipe smoking sessions, are considered current smokers.
Fruits and vegetables intake A dietary questionnaire is administered to collect information on dietary habits related to fruits and
vegetables intake. At least one intake per week will be considered an indicator for each type of dietary
intake.
Salt intake Measured in terms of urine spot sodium-to-creatinine ratio and 24-h urine sodium estimation by Kawaskai
formula [22]. (Chemistry analyzer [urine spot sodium]: Beckman Synchron Cx-7 by Ion Electrode; Regent
[urine spot sodium]: aluminum silicate; Chemical analyzer [urine spot creatinine]: Synchron Cx-7/Delta;
Regent [urine spot creatinine]: THC2)
Incident diabetes The use of hypoglycemic agents or fasting blood glucose ≥ 126 mg/dL at any time during the two-year
follow-up period for all participants without prevalent diabetes at enrollment. (Chemistry analyzer: Beckman
Synchron Cx-7/Delta; Reagent: GLUCm)
Cholesterol level Measured in terms of total cholesterol, high density lipoprotein cholesterol, low density lipoprotein
cholesterol, and triglycerides. (Chemistry analyzer: Roche Hitachi 912; Reagent: Roche reagents)
Estimated glomerular filtration rate Estimated using CKD-EPI equation [23].
Urine albumin excretion Measured in terms of urine albumin-to-creatinine ratio defined as a ratio of spot urine albumin divided by
spot urine creatinine expressed as mg/g. (Chemistry analyzer: Beckman Synchron Cx-7/Delta; Regent:
Pyrogallol red plus sodium molybdate)
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 Participating country (Bangladesh, Pakistan, Sri
Lanka)
 Cluster distance from the primary care clinic (Far, Near)
 Gender (Male, Female)
 Currently on anti-hypertensive medication (Yes, No)
 Poorly controlled BP (SBP ≥ 160 mmHg or DBP ≥
100 mmHg)
 Socioeconomic level (Poor, Non-poor)
Additional exploratory analysis may be performed to
evaluate the intervention effect for other outcomes for
the abovementioned sub-groups.
Safety objectives
To compare the MCI and usual care arms at the final
follow-up at two years post randomization for the following
endpoints:
 Proportion of participants who experienced any
serious adverse event (SAE)
 Proportion of participants who experienced any SAE
of special interest (death [all cause], hospital
admission due to coronary heart disease, heart
failure, or stroke)
On event of an AE, the site investigator will decide its
category and system organ class and also evaluate
whether an AE is an SAE if it leads to or is classified into
one or more of following categories: death; life-threatening;
disability or permanent damage; hospitalization (excludes
emergency room visits); prolongation of hospital stay (≥
24 h); required intervention to prevent permanent impair-
ment or damage; other SAEs. Table 3 lists the predefined
categories and system organ class for AEs.
SAEs reported with an onset date before the baseline
visit or after the final assessment visit at two years will
not be included in the analysis.
Potential covariates
The following baseline variables may be considered as
potential covariates in the supportive analyses:
 Age (in years)
 Gender (male, female)
 Education level (no formal education, formal
education)
 Marital status (single [never married, divorced,
separated, widowed], not single [married])
 Socioeconomic level (poor, middle, high)
 BMI (obese/overweight [≥ 23.5 kg/m2 BMI],
non-obese/not-overweight [< 23.5 kg/m2 BMI]) [6]
 Waist circumference
 Diabetes (yes, no)
 Chronic diseases (yes [heart disease, chronic kidney
disease, stroke], no)
 Currently using an anti-hypertensive medication
(yes, no)
 Current smoking status (yes, no)
 Physical activity score (inactive/minimally active,
highly active)
 Salt intake
○ Urine spot sodium-to-creatinine ratio
○ 24-h urine sodium
 Cholesterol level
○ Total cholesterol
○ High density lipoprotein cholesterol
○ Low density lipoprotein cholesterol
○ triglycerides
 Kidney function
○ Estimated glomerular filtration rate (eGRF)
○ Urine spot albumin-to-creatinine ratio
Potential moderators
The following variables recorded over time may be
considered as potential moderators in the supportive
analyses:
 BMI
 Waist circumference
 Adherence to anti-hypertensive medication
 Current smoking status
 Physical activity level
Populations
Intent-to-treat (ITT) population
The ITT population consisted of all enrolled participants
with a baseline visit (i.e. assessed for the primary and
secondary outcomes). Participants from the MCI clusters
will be included in the MCI arm even if they did not
receive the MCI. Similarly, participants from the usual
care clusters will be included in the usual care arm even if
they are exposed to the MCI.
Table 3 Predefined categories and system organ classes for
adverse events
Categories System organ classes
Angioedema and anaphylactic reaction
Peripheral edema
Hypotension
Coronary heart disease
Heart failure
Stroke or transient ischemic attack
Headache, dizziness, or lightheadedness
Flushing
Cough after initiating antihypertensive
Abdominal pain
Muscle pain
Falls and trauma
Other
Systemic reactions
Cardiovascular system
Nervous systems
Skin and appendages
Respiratory system
Gastrointestinal and
hepatobiliary system
Other
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Treated population
The MCI arm includes all enrolled participants who
have attended at least one interview on HHE or vis-
ited trained GPs (i.e. based on receipt of physician’s
management checklist) as a part of the MCI intervention.
The usual care arm includes all enrolled participants.
Participants from an MCI cluster who are considered to
have not been “treated” (i.e. have not attended any inter-
view on HHE and have not visited a trained GP as a part
of the MCI intervention) will be analyzed with the usual
care arm.
Per-protocol population
The per-protocol population consists of all enrolled
participants who do not have any significant protocol
deviations (described below).
Significant protocol violation/deviations including those
which could have an impact on the primary effectiveness
measures, those which present a safety risk to the partici-
pants, and/or those that are of ethical concern will be
identified during a blinded data review before database
lock.
General significant protocol violation/deviation criteria
are listed below:
 Eligibility deviations (included in the study despite
meeting following criteria)
1) Wrong hypertensive diagnosis: neither has
persistently uncontrolled BP (SBP ≥ 140 mmHg
or DBP ≥ 90 mmHg) nor on anti-hypertensive
medications.
2) Under age: aged < 40 years.
 On-study deviations (continued the study despite
meeting following criteria)
1) Pregnancy
2) Any major medical systemic illness which
precludes continuation
3) Error in intervention assignment: participants
treated with intervention arm different from the
assigned cluster’s intervention arm.
4) Withdraw consent or lost to follow-up
The above list of significant protocol deviation criteria
may be extended as appropriate.
All effectiveness analyses will be performed using the
ITT population. However, considering the nature of the
study (community-based cluster randomized trial with data
collection in rural parts of three developing countries),
there is a chance that a small proportion of participants
may not provide any follow-up data and hence they will not
contribute to the evaluation of intervention effectiveness. If
this proportion of participants is sizable, participant dispos-
ition, and demographic and baseline participant characteris-
tics will be analyzed using the ITT population, as well as
excluding participants who have not contributed in the
effectiveness analyses. The ITT and per-protocol popu-
lations may be used for additional supportive analysis
of effectiveness endpoints. Study intervention exposure
and safety analyses will be performed using the treated
population. The ITT population may also be used for
supportive safety analyses.
Statistical analyses
General methods and data handling rules
All observed data will be included in the ITT population,
with the exception of data collected outside the acceptable
assessment window (± 2 months) for each time point and
participants with no follow-up data. The frequency distri-
bution of the effectiveness outcomes will be reviewed, e.g.
using boxplots and histograms. Continuous variables with
excessive skewness and/or kurtosis will be analyzed using
appropriate methods for asymmetric data or considered
for transformation. All p values will be two-sided. A p
value < 0.05 for the primary analysis will be considered
statistically significant, in line with the prespecified level
used in the sample size calculation. All confidence inter-
vals (CI) will be at the 95% level. All statistical analyses
will be carried out using SAS software (SAS Institute, NC,
USA). After the statistical plan has been written and
signed off, and after the database for the final analysis has
been locked, the individual cluster’s assigned intervention
will be made known to the study team.
Trial profile
The number of participants enrolled into the study at
screening, reasons for screening failure, number of partici-
pants enrolled, number of participants who completed the
baseline and follow-up visits, mean and SD of cluster size
at each visit will be summarized by intervention arm using
the CONSORT flow chart [7]. The distribution of baseline
characteristics will be summarized by: (1) intervention
arm; and (2) country and intervention arm, with descrip-
tive statistics for the ITT population.
Intervention exposure
MCI exposure is evaluated using the HHE session delivery
rate, physician referral rate, and physician’s evaluation
rate. Table 4 defines these fidelity measures. The fidelity
measures are estimated along with corresponding 95% CI
for country for the MCI arm based on the treated
population. Exposure and adherence to anti-hypertensive
medications is summarized as secondary outcomes.
Primary effectiveness analysis
This primary analysis will be performed on the ITT
population. Change in SBP at two years from baseline is
the primary outcome. The four six-monthly change-
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from-baseline measurements (six months, 12 months, 18
months, and 24 months) from all participants will be
modelled simultaneously using a likelihood-based general-
ized linear mixed-model for repeated measures (MMRM)
based on a participant-level analysis, incorporating a cluster
random-effect, using Gaussian distribution and identity link
function [8, 9]. Appropriate distributions within the
exponential family and corresponding link functions
will be employed for the primary outcome in case of
non-normality. An unstructured matrix will be used to
model the residual variance-covariance structure within
participant. If this model fails to converge, heterogeneous
toeplitz, heterogeneous autoregressive of order one, auto-
regressive of order one, and compound symmetry struc-
tures will be considered in the specified order to model
the correlation between time points from the same partici-
pant. MMRM accounts for missing data and is valid under
the missing at random (MAR) assumption.
All primary analysis models will include fixed effects
for baseline SBP, country, indicator for distance from
clinic (far or near), age, gender, intervention arm, visit
number, and the intervention arm-by-visit number inter-
action. The primary outcome of interest at two years
from baseline will be estimated with corresponding 95%
CIs using the appropriate contrast at the final visit. We
will employ restricted/residual maximum likelihood with
the between-within approximation for degree of freedom
estimation [10].
Supportive effectiveness analyses
A MMRM model will be performed for SBP similar to
the primary analysis mentioned above including interactions
for country, intervention group, and time to determine
whether the effects differ by country. If the interaction effect
is found to be clinically meaningful, a MMRMmodel similar
to the primary analysis model will be performed separately
for each country. The country-specific analyses will use
Bonferroni corrected p values and CIs for evaluating
intervention effectiveness. Further analysis will be per-
formed similar to the primary analysis with each potential
confounder at a time as fixed effect (separate model for
each confounder) as well as all (or selected) potential
confounders at the same time as fixed effects (single
model including multiple confounders). The final list of
confounders will be decided considering statistical signifi-
cance (p < 0.1), effect size, and clinical importance. A
MMRM model will be performed for SBP similar to the
primary analysis mentioned above, including each moder-
ator at a time as fixed effect as well as all moderators at
the same time as fixed effects using the ITT population.
Further supportive analysis may be performed using the
ITT and per-protocol populations.
Secondary effectiveness analyses
Secondary effectiveness outcomes will be analyzed using
a similar strategy applied to the primary endpoint. That
is, using a MMRM with an unstructured variance-covari-
ance matrix. Appropriate distributions within the expo-
nential family and corresponding link functions will be
employed for each outcome. Analysis of incident diabetes
(for those without prevalent diabetes at baseline), salt in-
take, and cholesterol level will be based on only two
time-points (baseline and two years) using similar MMRM
models. All secondary analyses will be performed on the
ITT population. Supportive analyses may be performed
using the treated and per-protocol populations. Additional
supportive analyses may be performed to evaluated inter-
vention effect after adjusting for potential confounders.
Exploratory effectiveness analyses
A MMRM model will be performed for SBP similar to
the primary analysis mentioned above including a fixed
effect term for currently anti-hypertensive medication
(yes/no) at baseline and its interactions with intervention
group and time to determine whether the intervention
effect differs by anti-hypertensive medication use status
at baseline. Similar analysis will be performed for cluster
distance from the primary care clinic, gender, poorly
controlled BP status, and socioeconomic status at base-
line. If the interaction effect is found to be clinically
meaningful, a MMRM model similar to the primary
analysis model will be performed separately for each
sub-group. These analyses will be performed on the ITT
population.
Table 4 Intervention fidelity measures
Fidelity measure Definition
Home health education (HHE)
session delivery rate
Calculated as the total number of three-monthly HHE sessions delivered at the household level using the
Community Health Workers Monitoring and Home Health Education Checklist divided by the total number of
planned HHE sessions until the study discontinuation/completion, multiplied by 100.
Physician referral rate Calculated as the total number of times they are referred to trained physicians by CHWs using the General
Practitioner Referral Checklist divided by the total number of times participants identified with having poorly
controlled BP (SBP ≥ 160 mmHg or DBP ≥ 100 mmHg) during study visits until the study discontinuation/completion,
multiplied by 100.
Physician’s evaluation rate Calculated as the total number of times they are evaluated by trained physicians using the General Practitioner
Management Checklist divided by the total number of times participants identified with having poorly controlled BP
during study visits until the study discontinuation/completion, multiplied by 100.
Gandhi et al. Trials          (2018) 19:658 Page 8 of 11
Handling of missing data in the effectiveness analyses
The primary analysis is planned with no imputation for
missing data. The primary analysis, based on a likelihood-
based MMRM, is valid under the MAR assumption [11].
The MAR assumption means that missingness is inde-
pendent of the unobserved outcome values after account-
ing for the appropriate observed data and covariates in the
model.
In order to evaluate the robustness of the findings to
the MAR assumption, sensitivity analyses will be per-
formed under varying assumptions for data considered
likely to be missing under MAR, as well as missing not
at random (MNAR). MNAR means that missingness de-
pends on the unobserved values and cannot be predicted
solely based on the participant’s observed data. Several
types of statistical models have been proposed to analyze
clinical study data under such assumptions. We will use
two possible approaches to evaluate the impact of
missingness.
The first approach that will be implemented for this
study is the use of multiple imputations and MMRM for
the primary outcome. Using MI data for change in SBP
post baseline (six months, 12 months, 18 months, and
24 months from baseline measurements) from all partic-
ipants will be modelled simultaneously using MMRM
model same as the primary analysis.
It is expected that the majority of missing data will be
caused by participants discontinuing from the study
prematurely. The resulting missing data will have a
monotone pattern, meaning that once a participant has
missing data for a visit, data will be missing for all subse-
quent visits. It is also expected that a small amount of
non-monotone missing data (when participants skip
intermediate visits but return for evaluations at subse-
quent visits) will be present. The intermittent missing
data will be imputed using the Monte Carlo Markov
Chain (MCMC) method for multiple imputation before
the imputation of the monotone missing data [8].
The second approach is the use of pattern mixture
models (PMMs) and multiple imputations, which will be
implemented if the amount of missingness on the primary
outcome is > 25% or the difference in percentage of missing
data between the intervention arms is ≥ 15% [8]. PMMs
have the advantages of allowing transparent and clinically
interpretable formulations of the assumptions regarding
unobserved data [11, 12]. PMMs with delta (δ) adjustments
will be used and imputations will be based on an MNAR
clinical assumption that participants from the MCI arm
who discontinue at a given time point would have, on aver-
age, their unobserved efficacy score worse by some
amount, δ, compared with the observed efficacy score of
participants who continue to the next assessed time point.
For purposes of the sensitivity analyses, participants who
discontinue from the usual care arm are treated as if they
would have exhibited the same evolution of the disease and
same benefit from intervention with usual care as partici-
pants that stayed on the study. Delta values will be based
on the estimated intervention effect taken from the primary
analysis in the ITT population where values will vary from
0 to the estimated intervention difference in increments of
0.5 mmHg, so that one can assess at which point the study
conclusions change from favorable to unfavorable, that is,
so that one can find a tipping point. These will be based on
10 imputations δ-value. The magnitude of the tipping point
will then be interpreted clinically and the robustness of the
study conclusions to missingness evaluated.
Safety analysis
All on-study SAEs reported on SAE reporting forms will
be summarized by intervention arm, using the treated
population. The percentage and frequency of participants
who ever reported each type of SAE and SAE of special
interest along with system organ class will be tabulated. A
similar safety analysis may be performed on the ITT
population. All deaths, together with reasons, will be
summarized using counts by intervention arm based on
the ITT population.
Interim analyses
Planned interim safety analyses are to occur at every
six months from the start of the study. The interim ana-
lyses will summarize participant baseline characteristics
and on-study safety data by randomized group, as well as
pooled over all randomized groups, for the treated popula-
tion. The by randomized group analysis is reviewed by an
independent data safety and monitoring board. The study
team, except statisticians involved in performing the
interim analyses, is blinded to these results. The pooled
analysis (combined of randomized groups) is presented to
the study team.
Discussion
The COBRA-BPS trial is a pragmatic, multi-country,
cluster randomized, controlled trial of a MCI with poten-
tial to implement it on a wide scale nationally in the
participating countries and beyond. The study aims to
evaluate the benefits of the MCI and monitor potential
safety concerns for BP control in the rural communities
in south-Asian countries with low-resourced public health
infrastructures.
The cluster randomized study design is a pragmatic
study to mimic how the proposed intervention can be
rollout primarily using the existing infrastructure in
countries with different types of healthcare systems and
availability of resources. Therefore, it helps to evaluate
not just the effectiveness of the intervention in the
real-life setting but also its feasibility in implementation
with an estimate of required resources, time and costs.
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The study is planned to collect comprehensive data
covering the impact of the intervention on change in
participants’ BP control, anthropometry, life-style, diet,
medication, and health-related quality of life as well as
costs associated with medications and other medical
events. This holistic approach will help determine the
direct and indirect impact of the intervention on overall
health.
The primary statistical analysis will be performed using
the ITT principle. It will provide an estimate of effectiveness
of the intervention in presence of varying level of adherence
to the intervention and other protocol deviations. We have
also planned to perform the analysis based on the per-proto-
col population which will provide an estimate of in an ideal
and more controlled setting. Further sensitivity analyses will
help to explore the impact of the intervention under varying
statistical assumptions, controlling potential confounders
and subgroups of special interest.
As the MCI involves components such as HHE by
government CHWs, BP monitoring, and stepped-up refer-
ral by GPs, we expect that there will be some over- and
under-enthusiastic CHWs; also, variability in adherence to
the clinical guideline by GPs means the effectiveness of the
intervention may be impacted. However, as the interven-
tion is designed to roll out for a population-wide program,
variation in performance of individual CHWs and GPs are
of limited interest. Therefore, multilevel modeling incorp-
orating such micro-level effects is not considered as the
primary analytic approach. However, the main analysis is
designed to incorporate cluster and county level effects in
the analysis.
In summary, we have presented the statistical analysis
plan to evaluate the real-world impact of the MCI before
any post-baseline outcomes for effectiveness have been
analyzed. The a priori statistical analysis plan will avoid
reporting bias and data-driven analysis for the primary
and key secondary outcomes.
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